Rapamycin treatment for amyotrophic lateral sclerosis

Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

Jessica Mandrioli, MDa,*, Roberto D’Amico, MD, PhDb, Elisabetta Zucchi, MDc, Annalisa Gessani, BSPathd, Nicola Fini, MD, Antonino Fasano, MD, Claudia Caponnetto, MDe, Adriano Chiò, MD, FAANf, Eleonora Dalla Bella, MDe, Christian Lunetta, MD, Letizia Mazzini, MDg, Kalliopi Marinou, MDh, Gianni Soraruı, MD, PhDı, Sara de Biasi, PhDı, Domenico Lo Tartaro, MScı, Marcello Pinti, PhDı, RAP-ALS investigators group, Andrea Cossarizza, MD, PhDı

Abstract

Introduction: Misfolded aggregated proteins and neuroinflammation significantly contribute to amyotrophic lateral sclerosis (ALS) pathogenesis, hence representing therapeutic targets to modify disease expression. Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions. Rapamycin also expands regulatory T lymphocytes (Treg) and increased Treg levels are associated with slow progression in ALS patients.

Therefore, we planned a randomized clinical trial testing Rapamycin treatment in ALS patients.

Methods: RAP-ALS is a phase II randomized, double-blind, placebo-controlled, multicenter (8 ALS centers in Italy), clinical trial. The primary aim is to assess whether Rapamycin administration increases Th2s number in treated patients compared with control arm. Secondary aims include the assessment of safety and tolerability of Rapamycin in patients with ALS; the minimum dosage to have Rapamycin in cerebrospinal fluid; changes in immunological (activation and homing of T, B, NK cell subpopulations) and inflammatory markers, and on mTOR downstream pathway (S6RP phosphorylation); clinical activity (ALS Functional Rating Scale-Revised, survival, forced vital capacity); and quality of life (ALSAQ40 scale).

Discussion: Rapamycin potentially targets mechanisms at play in ALS (i.e., autophagy and neuroinflammation), with promising preclinical studies. It is an already approved drug, with known pharmacokinetics, already available and therefore with significant possibility of rapid translation to daily clinics. Findings will provide reliable data for further potential trials.

Ethics and dissemination: The study protocol was approved by the Ethics Committee of Azienda Ospedaliero Universitaria di Modena and by the Ethics Committees of participating centers (EudraCT n. 2016-002399-28) based on the Helsinki declaration.

Abbreviations: AFS = progression rate, ADR = adverse drug reaction, AE = adverse events, ALS = amyotrophic lateral sclerosis, ALSAQ-40 = Amyotrophic Lateral Sclerosis Specific Assessment Questionnaire, ALSFRS = Amyotrophic Lateral Sclerosis Functional Rating Scale, ALT (SGPT) = alanine aminotransferase, ANOVA = analysis of variance, AST (SGOT) = aspartate aminotransferase, BBB = blood-brain barrier, C9orf72 = chromosome 9 open reading frame 72, CNS = central nervous system, CRO = contract research organization, CSF = cerebrospinal fluid, CYP3A4 = cytochrome P-450 3A4, DSMB = Data Safety and Monitoring Board, eCRF = electronic case report form, FoxP3 = forkhead box P3, FTLD = frontotemporal lobar degeneration, FUS = fused in sarcoma, FVC = forced vital capacity, gamma GT = gamma glutamyltransferase; HIV = human immunodeficiency virus,
1. Introduction

Protein aggregates into neurons and glial cells are common features of amyotrophic lateral sclerosis (ALS) pathology, and have a key role in ALS initiation and progression: TDP43 proteinopathy is a hallmark of >95% of sporadic/nonmutated ALS.[1-2] Protein degradation machinery and autophagy have a crucial role in dealing with misfolded aggregated proteins.[3] In ALS several genes (UBQLN2, SQSTM1, OPTN, VCP, TBK1) have strong links with protein degradation pathways as their products contribute to recruitment of ubiquitinated proteins to the autophagosome. Autophagy is also required for the removal of aberrant stress granules involved in ALS pathology[4] and for downregulation of inflammasome activity, which is activated in response to cellular inclusions formation.[5] TBK1, OPTN, and SQSTM1 converge on autophagy and neuroinflammation, suggesting that compounds which affect both pathways may be promising.[6] A recent paper showed a function for C9orf72 at transcriptional level;[7] it promotes the expression of SQSTM1 and facilitates TDP43 clearance, and regulates immune responses.

2. Methods

2.1. Objectives

The primary objective is to assess whether different Rapamycin doses increase Treg number in ALS patients compared with the control arm.

Secondary objectives include the following:

1. Assessment of Rapamycin safety and tolerability in a cohort of ALS patients: occurrence of adverse events (AEs), changes on clinical examination including vital signs and weight, and laboratory examinations (biochemistry, hematology and urinalysis) will be registered throughout the entire study duration.

2. Biological assessment: To analyze Rapamycin efficacy in inhibiting mTOR pathway, by quantifying the phosphorylation of the S6 ribosomal protein (S6RP) comparing baseline and weeks 8, 18 (treatment end), 30, and 54 between Rapamycin arms and placebo arm. To identify changes in activation and homing capabilities of different T, B, NK cell subpopulations comparing baseline and weeks 8, 18 (treatment end), 30, and 54 between Rapamycin arms and placebo arm. To study Rapamycin effects on different biomarkers (including peripheral and CSF biomarkers, that is, creatinine and albumin, CK, vitamin D, plasma/CSF neurofilament heavy/light chain protein) comparing baseline and week 8, 18 (treatment end), 30, and 54 between Rapamycin arms and placebo arm. To identify Rapamycin-induced changes in inflammatory status, by the molecular analysis of the inflammasome system baseline and week 8, 18 (treatment end), 30, and 54 between Rapamycin arms and placebo arm.

3. Clinical assessment: to assess changes in Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) - Revised from baseline to weeks 4, 8, 12, 18, 30, 42, and 54 in placebo and treatment arms; overall survival from randomization to date of documented death or tracheostomy; survival rate at weeks 18, 30, 42, and 54; forced vital capacity (FVC) score from baseline to weeks 4, 8, 12, 18, 30, 42, and 54.

4. Quality of life assessment: ALSAQ-40 from baseline to weeks 8, 18, 30, and 54 in treatment and placebo arms.

2.2. Design of the study

This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. It has been designed following the guidelines on clinical investigation of medicinal products for the treatment of ALS provided by the European Medicines Agency and adopted by the Agenzia Italiana del Farmaco. The...
The protocol has been discussed and revised according to the suggestions of the Data Safety and Monitoring Board (DSMB). The DSMB includes:

- Prof. Lawrence Korngut, University of Toronto.
- Prof. Paola Minghetti, University of Milan.
- Dr Graziella Filippini, IRCCS Foundation “Carlo Besta” Neurological Institute, Milan.
- Dr Ettore Beghi, IRCCS “Mario Negri” Institute, Milan.

The protocol (version 2, April 21, 2017) has been designed adhering to the Standard Protocol Items for Randomized Trials (SPIRIT). The trial has been registered on EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002399-28/IT) and on Clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT03359538?term=rapamycin&cond=Amyotrophic+Lateral+Sclerosis&rank=1)

Figure 1 shows the design of the study.

### 2.3. Eligibility criteria

Patients affected by probable (clinically or laboratory supported) or definite ALS [19] will undergo screening procedures that must be completed during the 14-day screening period. All patients must adhere to inclusion and exclusion criteria (Table 1) through

Table 1

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient diagnosed with a laboratory supported, clinically “probable” or “definite” ALS according to Revised EEC</td>
<td>Prior use of Sirolimus</td>
</tr>
<tr>
<td>Familial or sporadic ALS</td>
<td>Prior allergy/sensitivity to Sirolimus or macrolides</td>
</tr>
<tr>
<td>Age between 18 and 75 y old</td>
<td>Any medical disorder that would make immunosuppression contraindicated, including but not limited to, acute infections requiring antibiotics, patients with known diagnosis of HIV, tuberculosis, hepatitis B or C infection or history of malignancy</td>
</tr>
<tr>
<td>Disease duration from symptoms onset ≤18 mo at the screening visit</td>
<td>Severe comorbidities (heart, renal, liver failure), autoimmune diseases or any type of interstitial lung disease</td>
</tr>
<tr>
<td>Patient treated with a stable dose of Riluzole (100 mg/d) for ≥30 d before screening</td>
<td>White blood cells &lt;4000/mm³, platelets count &lt;100,000/mm³, hematocrit &lt;30%</td>
</tr>
<tr>
<td>Patients with a weight ≥50 kg and a BMI ≥18</td>
<td>Patient who underwent non invasive ventilation, tracheostomy and/or gastrostomy</td>
</tr>
<tr>
<td>Patient with a FVC ≥70% predicted normal value for gender, height, and age at the screening visit</td>
<td>Women who are pregnant or breastfeeding</td>
</tr>
<tr>
<td>Patient able and willing to comply with study procedures as per protocol</td>
<td>Participation in pharmacological studies within the last 30 d before screening</td>
</tr>
<tr>
<td>Patient able to understand, and capable of providing informed consent at screening visit before any protocol-specific procedures</td>
<td>Patients with known SOD1 mutation or with FALS and family members carrying SOD1 mutation</td>
</tr>
<tr>
<td>Use of effective contraception both for males and females</td>
<td></td>
</tr>
</tbody>
</table>

clinical evaluation and laboratory and instrumental assessment. Screening assessments include blood sampling, biochemical and pregnancy evaluations (for fertile females) which will be performed in the site’s local laboratory, general and neurological examinations, MRC, ALSFRS-R, chest radiography and ECG, and spirometry.

2.4. Randomization

Eligible patients will be randomized strictly sequentially, according to a randomization list prepared by the Biostatistician of the University of Modena.

All patients will receive a unique patient identification number at screening visit when signing the informed consent and before any study procedures are performed. Sixty-three patients will be randomized in the following 3 groups:

1. 21 patients will receive Rapamycin 2 mg/m^2/d + riluzole.
2. 21 patients will receive Rapamycin 1 mg/m^2/d + riluzole.
3. 21 patients will receive placebo + riluzole

2.5. Stratification

Randomization will be performed online. Patients will be stratified according to AFs (<20.7)[29] with 1:1:1 allocation in 3 treatment arms (Rapamycin 1 mg/m^2/d; Rapamycin 2 mg/m^2/d, placebo). The investigators will randomize patients directly online. Treatment will begin within 14 days from randomization. In case of discontinuation from the study, the randomization number will not be reused.

2.6. Experimental drug preparation

Pfizer S.r.L. gave the active treatment (Rapamycin) free of charge. Euromed Clinical Supply Services (ECLISSE) (Cantù (Como), Italy; http://www.css.euromed.it/en/) prepared the active formulation and the placebo. The active powder and the investigational drug have been produced complying the Good Manufacturing Practices of the European Union for active pharmaceutical ingredients and ICH Q7A guidelines. Verum and placebo are identical and unrecognizable tablets by form size, weight, and color, and will be indistinguishable to patients and neurologists.

2.7. Treatment and blindness

This study is a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RCT) to test Rapamycin in ALS patients. The study will include 63 ALS patients (EL Escorial Revised Criteria, sporadic and familial) with 1:1:1 allocation in 3 groups of 21 subjects each; treatment will be double blinded, and will last 18 weeks. Active treatment will include oral Rapamycin at 1 mg/m^2/d or 2 mg/m^2/d.

Rapamycin levels will be regularly measured and revealed only by a number and corresponding to different blinded code, and to all patients and doctors. Rapamycin levels will be regularly measured and revealed only by a number and corresponding to different blinded code, and to all patients and doctors. Rapamycin levels will be regularly measured and revealed only by a number and corresponding to different blinded code, and to all patients and doctors.

After treatment end (week 18) patients will be followed up for further 36 weeks. This large period of follow-up has the aim to assess potential late side effects of the treatment and to assess whether eventual biological or clinical effects of the treatment with respect to placebo, may last after drug discontinuation.

For the first 10 patients enrolled, clinical and biological safety assessments will be performed every week for the first month, and then every 2 weeks until the end of treatment. For the remaining 53 patients clinical assessments will be performed every 2 weeks for the first month, and then every 4 weeks during treatment duration.

If at either the interim or the final analyses safety concerns will arise, the trial will be stopped and all available data will be reviewed by the Study Steering Committee.

Table 2 shows study procedures to be undertaken.

2.8. Concomitant treatments

Patients must have been treated for a minimum of 1 month with a stable dose of riluzole (100mg/d) at baseline. Safety issues related to riluzole will be managed according to usual practice.

Treatment of ALS impairments (dysphagia, dysarthria, grip strength, communication) will be done with a multidisciplinary approach and accordingly to EFNS Guidelines for ALS patients management.[21]

As for prohibited treatments Rapamycin is known to be a substrate for both cytochrome P-450 3A4 (CYP3A4) and plasma glycoprotein (P-gp). Inducers of CYP3A4 and P-gp may decrease Rapamycin concentrations, whereas inhibitors of CYP3A4 and P-gp may increase Rapamycin concentrations. Concomitant use of strong inducers is not recommended, whereas it is forbidden concomitant use of strong inhibitors of CYP3A4 and P-gp.

Alternative agents with lesser interaction potential with Rapamycin should be considered.

Immunosuppressants may affect response to vaccination. Therefore, during treatment with Rapamycin, vaccination may be less effective. Because grapefruit juice inhibits the CYP3A4-mediated metabolism of Rapamycin, it will not be allowed to take with or be used for dilution of Rapamycin.

2.9. Outcomes

The primary outcome is represented by the change from baseline to week 18 in Treg number in ALS patients treated with Rapamycin compared with the control arm.

Secondary outcomes are as follows:

1. **Safety**: Occurrence of AEs and per-treatment arising changes in physical examination, vital signs (blood pressure, pulse rate, and body temperature), body weight, and clinical laboratory tests (biochemistry, hematology). MedDRA dictionary is going to be used for reporting.
2. **Rapamycin levels in CSF at week 18** (high-performance liquid chromatography (HPLC) with mass spectrometry (MS) (LC–MS/MS).
3. **Change from baseline to each time point (weeks 8, 18, 30, and 54)** of the phosphorylation of the S6 ribosomal protein (S6RP) comparing Rapamycin arms and placebo arm.
4. **Change from baseline to each time point (weeks 8, 18, 30, and 54)** of the activation and homing capabilities of different T, B, NK cell subpopulations comparing Rapamycin arms and placebo arm.
5. **Changes from baseline to each time point (weeks 8, 18, 30, and 54)** in different biomarkers (including peripheral and CSF biomarkers that is, creatinine and albumin, CK, vitamin
D, plasma/CSF neurofilament heavy/light chain protein) comparing Rapamycin arms and placebo arm.
6. Changes from baseline to each time point (weeks 8, 18, 30, and 54) in inflammatory status (molecular analysis of the inflamasome system) comparing Rapamycin arms and placebo arm.
7. Change from baseline to each time point (weeks 4, 8, 12, 18, 30, 42, and 54) of ALSFRS-R.
8. Survival defined as the time from randomization to the date of documented death or tracheotomy.
9. Survival rate at weeks 18, 36, and 54.
10. Change of FVC from baseline to each time point (weeks 4, 8, 12, 18, 30, 42, and 54).
11. Absolute and relative change from baseline in ALSAQ-40 (Amyotrophic Lateral Sclerosis Specific Assessment Questionnaire at weeks 4, 8, 12, 18, 30, 42, and 54).

2.10. Adverse events

AEs (serious and nonserious AEs), adverse drug reaction (ADR), and unexpected ADR will be defined accordingly to “ICH Guidance for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.”

All AE occurring between the first study-related procedure and the last study-related procedure will be reported. Those meeting the definition of serious AE (SAE) will be reported in an ad hoc SAE Form; they will be reported to coordinating center within 24 hours.

The following AEs have been reported during the use of Rapamycin, mainly in transplanted patients and in association with other drugs (Table 3).

Investigators must adhere to specific safety rules established for the following toxicities, regardless of the causal relationship to study treatment: respiratory toxicity; metabolic toxicity; cardiovascular toxicity; gastrointestinal toxicity; hematological toxicity; genitourinary toxicity; renal toxicity; reproductive system and pregnancy; hypersensitivity Reactions; skin toxicity; carcinogenicity; and increased susceptibility to infection.

The risk management plan for AEs not described above and suspected to be related to study treatment is as follows:
- At the first occurrence of moderate AE (grade 2): study treatment will be interrupted until AE has returned to baseline value or mild intensity, then resumed at the same dose level according to local investigator judgment.
- If the same moderate AE recours, study treatment will be interrupted.
- In case of severe AE (grade 3), study treatment will be interrupted until AE has returned to baseline level or mild intensity, then resumed with a dose reduction (1 step).
- In case of life-threatening or disabling AE (grade 4), study treatment must be definitely discontinued.

2.11. Safety assessment

Safety will be assessed on the following variables: occurrence of AEs and per-treatment arising changes in physical examination, vital signs (blood pressure, pulse rate, and body temperature), body weight, and clinical laboratory tests (biochemistry, hematology). MedDRA dictionary is going to be used for reporting.

All AEs will be actively collected at each visit, from spontaneous declarations of the patient as well as from oral inquiry and clinical examination. All concomitant medications and/or therapies should be documented in the patient file and reported in the electronic Case Report Form (eCRF).

The following biological parameters will be assessed according to study flow chart (Table 2)—hematology: count of red blood cells, hemoglobin, hematocrit, total white blood cells count, platelet count, and a differential count including neutrophils, lymphocytes, monocytes, eosinophils, and basophils; biochemistry includes urea, creatinine, albumin, protein electrophoresis, AST (SGOT), ALT (SGPT), gamma GT, LDH, cholesterol, triglycerides, sodium, potassium, glucose; screening for infectious diseases including HIV, hepatitis B, hepatitis C, and tuberculosis. An electrocardiogram and chest X-ray (only posterior–anterior view) will be performed at screening. At treatment end (week 18) these exams can be repeated based on clinical opinion of the caring neurologist.

A physical examination including vital signs (systolic and diastolic arterial pressure, heart rate) and body weight will be performed according to the Visit Schedule (Table 2). Check for adequate contraception will be performed at every visit. Respiratory function will be monitored with FVC.

Stopping rules for single patient have been established for each AE.

Stopping rule for the RCT has been established too. We will consider the following list of toxicities as acceptable: peripheral edema, hypertriglyceridemia, hypercholesterolemia, constipation, arthralgia, thrombocytopenia (not severe), anemia (not severe), leukopenia (not severe), rash, hypertension, increased creatinine, abdominal pain, diarhoea, headache, fever, urinary tract infection, nausea, lymphocele, tachycardia, stomatitis, abnormal healing, increased lactate dehydrogenase, hypokalemia (not severe), diabetes mellitus, epistaxis, ovarian cysts, and menstrual disorders (amenorrhea and menorrhagia).

The study will be stopped by the DSMB in case of >30% of patients experience one of the following side effects: pneumonia, sepsis, venous thromboembolism, thrombotic thrombocytopenic purpura/hemolytic uricemic syndrome, severe leukopenia or anemia or thrombocytopenia, bone necrosis, melanoma, and skin cancer. In other words, the trial will be stopped if any of the abovementioned SAEs occurs in ≥6 patients.

As for mild and moderate AE, the DSMB will be notified if ≥50% of all subjects report a given mild or moderate severity adverse effect.

2.12. Data recording and data monitoring

The investigators will collect data by entering them directly into the trial database, through electronic case report forms ad hoc developed. At the end of the RCT, database will be locked and an expert Statistician will check the database and extract all data for statistical analyses.

The study will be monitored by a certified contract research organization (CRO). A monitor will be in charge of safety data downloads and review on monthly basis (AEs), laboratory data downloads, including Rapamycin levels on fortnightly basis. Data safety and monitoring board (DSMB) meetings will be scheduled (starting when the first 10 patients enrolled would have been treated for 3 months and then when 50% of patients would have completed at least week 9 of treatment and subsequently after every 3 months). All SAEs will be reviewed by the DSMB. As for mild and moderate AEs, the DSMB will be notified if ≥50% of all subjects report a given mild or moderate severity adverse effect.
### Table 2

**Study flowchart (excluding the first 10 patients, for whom additional visits are scheduled).**

<table>
<thead>
<tr>
<th>Examinations</th>
<th>Pretreatment</th>
<th>Treatment</th>
<th>Treatment end</th>
<th>Follow-up</th>
<th>Study end</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Examinations</strong></td>
<td><strong>Baseline (W0)</strong></td>
<td><strong>W1, W3, W5, W7, W9, W11, W13, W15, W17</strong></td>
<td><strong>W2, W6</strong></td>
<td><strong>W4, W8, W12</strong></td>
<td><strong>W18</strong></td>
</tr>
<tr>
<td><strong>Time window</strong></td>
<td>&lt;2 weeks from screening</td>
<td>± 1 d</td>
<td>± 1 d</td>
<td>± 1 d</td>
<td>± 2 ds</td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion exclusion criteria</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient able to understand and follow the patient card procedures</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone call</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biological activity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tregs</td>
<td>x</td>
<td></td>
<td>x(1)</td>
<td>x</td>
<td>x(2)</td>
</tr>
<tr>
<td>Lymphocytes phenotype</td>
<td>x</td>
<td></td>
<td>x(1)</td>
<td>x</td>
<td>x(2)</td>
</tr>
<tr>
<td>SRP phosphorilation</td>
<td>x</td>
<td></td>
<td>x(1)</td>
<td>x</td>
<td>x(2)</td>
</tr>
<tr>
<td>Inflammasome</td>
<td>x</td>
<td></td>
<td>x(1)</td>
<td>x</td>
<td>x(2)</td>
</tr>
<tr>
<td>Peripheral biomarkers</td>
<td>x</td>
<td></td>
<td>x(1)</td>
<td>x</td>
<td>x(2)</td>
</tr>
<tr>
<td>CSF</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Safety assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Vital signs</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Physical examination</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
<td>(3)</td>
</tr>
<tr>
<td>ECG</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious markers</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rapamycin blood dosage</td>
<td></td>
<td>Only at week 1</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td><strong>Clinical assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological examination</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ALSFRS-R</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>MRC</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>FVC</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>BMI/BSA</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td><strong>Quality of life assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALSQ40</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Study treatment dispensation and compliance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study treatment dispensation</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study treatment compliance</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

(1) Only at week 8; (2) only at week 30; (3) only if necessary on medical opinion.
<table>
<thead>
<tr>
<th>Systems involved</th>
<th>Very common (≥ 10%)</th>
<th>Common (1%–10%)</th>
<th>Uncommon (0.1%–1%)</th>
<th>Rare (&lt; 0.1%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory</strong></td>
<td>Dyspnea, upper respiratory infection, pharyngitis</td>
<td>Pneumonia, episitis, pleural effusion, episistis</td>
<td>Pulmonary hemorrage</td>
<td>Alveolar proteinosis</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td>Hyperglycemia, hypercholesterolemia, hypokalemia, hyperphosphatemia, hyperglycemia</td>
<td>Abnormal healing, increased LDH, hypokalemia, diabetes mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>Peripheral edema, hypertension, chest pain, edema, lymphocoele</td>
<td>Venous thromboembolism (including pulmonary embolism), deep venous thrombosis, tachycardia</td>
<td>Pericardial effusion, lymphedema</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>Constipation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia</td>
<td>Stomatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td>Anemia, thrombocytopenia, blood lactate dehydrogenase increased, blood creatinine increased</td>
<td>Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, leukopenia, neutropenia, aspartate aminotransferase increased, alanine aminotransferase increased</td>
<td>Pancytopenia</td>
<td></td>
</tr>
<tr>
<td><strong>Genitourinary</strong></td>
<td>Urinary tract infection</td>
<td>Pyelonephritis, decline in renal function (creatinine increased) in long-term combination of cyclosporine with this drug, ovarian cysts, menstrual disorders, proteinuria</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td>Arthralgia</td>
<td>Bone necrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system</strong></td>
<td>Headache</td>
<td>Tremor, insomnia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dermatologic</strong></td>
<td>Acne, rash</td>
<td>Herpes zoster, herpes simplex</td>
<td>Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, leukopenia, melanoma, squamous cell carcinoma, basal cell carcinoma</td>
<td></td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Creatinine increased</td>
<td>Nephrotic syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatic</strong></td>
<td>Liver function tests abnormal</td>
<td>Hepatic failure, hepatic artery thrombosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypersensitivity</strong></td>
<td></td>
<td></td>
<td>Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, eosinophilic dermatitis, and hypersensitivity vasculitis</td>
<td></td>
</tr>
<tr>
<td><strong>Oncologic</strong></td>
<td></td>
<td></td>
<td>Focal segmental glomerulosclerosis, BK virus associated nephropathy, nephrotic syndrome, higher serum creatinine levels, lower glomerular filtration rates</td>
<td></td>
</tr>
<tr>
<td><strong>Immunologic/Infections</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fever, pain</strong></td>
<td></td>
<td></td>
<td>Impaired healing</td>
<td></td>
</tr>
</tbody>
</table>
2.13. Sample size calculation

The sample size has been estimated considering as the primary outcome measure the proportion of positive response (Tregs number increase) at treatment end (18 weeks) in patients treated with Rapamycin versus placebo.

ALS patients have a slight reduction of Treg% (mean±SD: 2.1±0.7) with respect to healthy controls (2.6±0.6) (Treg% calculated on total lymphocytes; normal values of total lymphocytes: 1000–4500/μL; normal values of total Treg: 71.5±17/μL).²²

Slowly progressive ALS patients have a number of Tregs that is equal to healthy controls, whereas fast progressors have 31% fewer Tregs than slowly progressing patients, and Treg% is inversely correlated with the rate of disease progression.[⁸] These data indicate that ALS patients have 60±17 Treg/μL (fast progressors: 49.3 Treg/μL; slow progressors: 71.5 Treg/μL). As a result, a “positive response” can be considered an increase of the proportion of Tregs by ≥30%. The null hypothesis is that Rapamycin does not increase significantly the proportion of positive responses in treated patients at 18 weeks compared with their baseline stage and to placebo group. The alternative hypothesis is that Rapamycin determines a proportion of positive responses in ≥50% of treated patients compared with a maximum 5% of patients in the placebo group. The study has been designed to reject the null hypothesis with an alpha error of 0.025 (to take into account a multiple comparison with a control arm) and a power of 0.80. For this purpose, a sample of 54 patients randomized in 3 treatment arms would be needed. Considering an average drop out of 15% then a recruitment of 63 patients will be necessary.

2.14. Statistical analyses

Separate analyses will be performed in

1. all randomized subjects receiving ≥1 dose of study medication (intention-to-treat population);
2. all randomized subjects excluding protocol deviations (per protocol, PP population).

Descriptive statistics will be performed comparing the 2 groups of Rapamycin treatment and placebo. Continuous variables will be described using mean and standard deviation or median and interquartile range; categorical variables will be described as counts and percentages.

Safety analysis will be performed in all subjects receiving ≥1 dose of the experimental drug. All AEs, SAEs, and AEs leading to treatment discontinuation will be recorded according to ICH Guidelines, listed, and compared in the treatment arms at any follow-up visit and at the end of the study.

Differences in tracheostomy-free survival (Kaplan–Meier method) between the treated groups and placebo group will be compared using the log-rank test. Cox’s proportional hazard model would be used to adjust for any possible unbalanced prognostic factors. Statistical significance will be set at 0.05 level for a 2-tailed test. Missing data will be handled using the last observation carried forward.

 Immune response to Rapamycin will be analyzed as the difference in positive response to Rapamycin (mean Tregs increase ≥30%) between the placebo group and the Rapamycin groups. This will be calculated with the use of Treg data obtained at baseline and at week 18.

We will compare the mean values of S6RP phosphorylation, of different T, B, NK cell subpopulations, of biomarkers, inflammasome, cytokines, comparing baseline and treatment end (18 weeks) between Rapamycin and placebo arm. Mean differences in plasma concentrations from baseline to week 18 in the 2 treatment arms will be calculated and compared using t test or Wilcoxon–Mann–Whitney test.

The mean change over time for the same variables as above will be assessed using repeated measures ANOVA, with treatment as between-subjects factor and time as within-subjects factor. Different models will be used, each with a different biomarker of activity as the dependent variable. Models will be adjusted for any unbalanced distribution of the main prognostic factors (e.g., age) between the 2 treatment arms.

2.15. Role of participating centers

Our study group includes 8 centers (Turin, Modena, Genoa, Padua, Novara, and 3 centers in Milan) that have a longstanding history on ALS management, and are referral centers for ALS care following >150 patients/each. They share an established collaboration in the field of ALS, in clinical management of patients, in the realization of clinical trials, genetic, and epidemiological studies. The analysis of biomarkers will be centralized and performed in a renowned laboratory (University of Modena and Reggio Emilia), with large experience in cell analysis and is internationally renowned for the use of flow cytometry for studies on several human diseases. Randomization and statistics will be also centralized to orchestrate the different phases of the project. Statistical Unit of the University of Modena and Reggio Emilia has considerable experience on RCT project and management, and on data analysis. All trial activities will be monitored by a CRO.

Each center is expected

1. to randomize ≥7 patients fulfilling including and excluding criteria in a period of 12 months and to administer the treatment for 18 weeks;
2. to provide 1 principal investigator and 1 neurologist to evaluate including and excluding criteria, get an informed consent, administer treatment, and assess primary and secondary outcome;
3. to provide a person who will send Rapamycin dosage to the coordinating center and who will not see patients; and
4. to formally adhere to the practice parameters of the European Federation of Neurological Societies concerning the standardization of the management of the patient in terms of ventilatory support and nutrition.

2.16. Ethics and dissemination

The study will be carried out in accordance with the Declaration of Helsinki, as amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013.

The results of the study will be presented during scientific symposia or published in scientific journals only after review and written approval by the involved parties in full respect of the privacy of the participating subjects.

An insurance company will provide insurance coverage for damages emerging from the trial and involving test subjects treated with the test compound.

3. Discussion

An urgent unmet need persists for effective therapies in ALS. The absence of reliable biomarker for disease progression and drugs activity is an important target to be addressed too. This is going to
be a randomized clinical trial using a drug (Rapamycin) which potentially targets important mechanisms at play in ALS, in particular autophagy and neuroinflammation.

Preliminary data show that in 2 cell lines, inhibition of mTOR by Rapamycin reduced TDP43 fragments accumulation and restored TDP-43 nuclear localization. In murine and in human stem cell-derived neurons and astrocytes with mutant TDP43, autophagy enhancement improved TDP43 clearance and localization and enhanced survival, showing that autophagy induction mitigates neurodegeneration by TDP43 clearance. In cultured neuronal cells expressing mutant ALS-causing FUS, Rapamycin reduced FUS-positive stress granules, as well as neurite fragmentation and cell death in neurons expressing mutant FUS under oxidative stress. In induced pluripotent stem cells derived from ALS patient, activation of autophagic mechanisms with Rapamycin reduced the accumulation of p62.

Early Rapamycin administration to a mouse model with FTLD and cytoplasmic TDP43 ubiquitine inclusions (UBIs) rescued learning/memory deficiencies and motor function disorders. This was associated with reduction of neuronal loss and of TDP43 UBIs. Treatment of zebrafish embryos with Rapamycin yielded an amelioration of locomotor phenotype in a SQSTM1 knock-down model. Treatment with Rapamycin of larvae of a Drosophila model carrying VAPB (P58S) mutation determined reversal of VAP (P58S) bouton phenotypes, and Rapamycin decreased the severity locomotive defects in a TDP-43/ALS Drosophila model.

Furthermore, inducing autophagy with Rapamycin was shown to improve in vivo pathology of transgenic mice harboring a disease-causing VCP mutation.

However, the failure of Rapamycin with aggravation of neuronal death has also been reported in mSOD1 mice. In this study, mSOD1 mice (which reflects the pathogenic mechanisms of SOD1 ALS, whereas the majority of ALS presents TDP43 UBIs) were treated with 2mg/kg body weight/d, a dosage >50 times higher than that used in clinical practice (usually 2mg/d), which gives blood concentrations that have well known toxic effects. A further study showed that this effect was due to excessive immunosuppression, as the treatment on ALS mice lacking mature lymphocytes increased ALS survival. However, being the evidences on Rapamycin action mainly on models linked to TDP43 pathology, we will exclude patients carrying SOD1 mutations.

As mTOR has a role in organisms longevity, Rapamycin has been tested to this extent and it resulted to extend the lifespan of various mouse strains. Rapamycin, then, has been shown to protect against several types of neuronal injury (stroke, atherosclerosis, traumatic brain, and spine injury). Recently, it resulted effective in improving respiratory function in lymphangioleiomyomatosis.

Rapamycin has a well-known immunosuppressive action: it is used for the cure of transplanted patients, and in clinical trials to test efficacy in autoimmune disorders, CNS tumors, and other neurological disorders (such as tuberous sclerosis).

As for the role of immunity in ALS, recent studies suggest that innate and adaptive immune systems contribute to ALS progression. Mso1 Tregs cocultured with activated Mso1 microglia attenuated the expression of microglial toxic factors by IL4 release, and promoted MN survival by suppressing M1 activation, inducing an M2 protective phenotype, and reducing the release of ROS. Tregs passive transfer into ALS mice prolonged survival, and FoxP3 mRNA in mSOD1 mice spinal cord decreased with disease progression. In patients, blood Treg percentage inversely correlated with ALS progression rate, and FoxP3 levels were early predictors of ALS progression and survival. These data were confirmed in postmortem studies. Inhibiting the mTOR pathway, Rapamycin induces de novo FoxP3 expression and expands Tregs.

The entity of the increase of Tregs induced by Rapamycin is completely unknown in ALS patients. For this reason, we are planning this first trial focused on showing immunological targets engagement by Rapamycin in ALS patients. Moreover, given its large natural structure, there was initial concern that Rapamycin might not be able to cross the BBB; however, in one study sufficient levels of Rapamycin could be found in brain tumors when administered at therapeutic doses. To further address this concern, we are planning to test Rapamycin titer in CSF at treatment end with LC–MS/MS (using HPLC). This procedure will also allow to understand if Rapamycin action depends on BBB crossing or on its action on Treg cells.

In conclusion, the study will give extensive inference to a possible effect of Rapamycin on biomarkers of disease progression. Rapamycin is an already approved drug, with known pharmacokinetics, which is available and therefore there is significant possibility of transferability to patients, and of a rapid translation to daily clinics. This short study will optimize time and resources to get reliable information for a following RCT to test Rapamycin clinical efficacy in ALS.

Acknowledgments

The authors acknowledge RAP-ALS investigators group:

- Department of Neuroscience, St. Agostino Estense Hospital, Azienda Ospedaliero Universitaria di Modena, Modena, Italy (J. Mandrioli, N. Fini, A. Fasano, E. Zucchi, A. Gessani, P. Nichelli)
- Unit of Statistics, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy (R. D’Amico, R. Vicini)
- Department of Neurosciences, Rehabilitation Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, Italy (G. Capone, G. Cabonetti)
- Neurological Institute, Milan, Italy (G. Lauria, E. Dalla Pozza)
- Azienda Ospedaliero Universitaria di Modena, Modena, Italy (J. Mandrioli, N. Fini, A. Fasano, E. Zucchi, A. Gessani, P. Nichelli)
- Department of Neuroscience, Rehabilitation Ophthalmology, Genetics, Mother and Child Disease, Ospedale Policlinico San Martino, Genova, Italy (G. Capone, G. Cabonetti)
- 3rd Neurology Unit and ALS Centre, IRCCS “Carlo Besta” Neurological Institute, Milan, Italy (G. Lauria, E. Dalla Bella)
- NEMUScular Omnicanter, Serena Onlus Foundation, Milan, Italy (C. Lunetta, F. Gerardi)
- ALS Centre, Neurologic Clinic, Maggiore della Carità University Hospital, Novara, Italy (L. Mazzini, A. Scognamiglio, F. De Marchi)
- ALS Center, “Salvatore Maugeri” Clinical-Scientific Institutes, Milan, Italy (G. Mora, K. Marinou)
- Department of Neurosciences, University of Padua, Padua, Italy (G. Sorarù, M. Gizzi)
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy (M. Pinti, S. De Biasi)
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia School of Medicine, Modena, Italy (A. Cossarizza, D. Lo Tartaro)
Author contributions

Conceptualization: JESSICA MANDRIOLI, Roberto D’Amico, Claudia Caponnetto, Adriano Chiò, Sara De Biasi, Marcello Pinti, Andrea Cossarizza.


Formal analysis: JESSICA MANDRIOLI, Marcello Pinti, Andrea Cossarizza.

Funding acquisition: JESSICA MANDRIOLI, Roberto D’Amico, Marcello Pinti, Andrea Cossarizza.


Methodology: JESSICA MANDRIOLI, Roberto D’Amico, Sara De Biasi, Domenico Lo Tartaro, Marcello Pinti, Andrea Cossarizza.

Project administration: JESSICA MANDRIOLI, Andrea Cossarizza.

Resources: JESSICA MANDRIOLI, Andrea Cossarizza.

Software: Roberto D’Amico.

Supervision: JESSICA MANDRIOLI, Adriano Chiò, Marcello Pinti, Andrea Cossarizza.

Validation: JESSICA MANDRIOLI.

Visualization: JESSICA MANDRIOLI, Andrea Cossarizza.

Writing – original draft: JESSICA MANDRIOLI, Elisabetta Zucchi, Annalisa Gessani, Nicola Fini, Sara De Biasi, Domenico Lo Tartaro.

Writing – review and editing: Roberto D’Amico, Claudia Caponnetto, Adriano Chiò, Eleonora Dalla Bella, Christian Lunetta, Letizia Mazzini, Kalliopi Marinou, Gianni Sorarù, Marcello Pinti, Andrea Cossarizza.

References


